# Neoplasms, Head and Neck FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/neoplasms-head-and-neck

> 2 upcoming FDA catalysts in neoplasms, Head and Neck: Jemperli (dostarlimab, GSK) on Jun to Sep 2028 (topline data readout); Jemperli (dostarlimab, GSK) on June 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 10, 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | completed | "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06062420)) |
| Sep to Dec 2026 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | scheduled | "NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06062420)) |
| Jun to Sep 2028 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | scheduled | "NCT06256588 (A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06256588)) |
| June 2028 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Head and Neck | scheduled | "NCT06256588 (A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06256588)) |

## Drugs

- [Jemperli (dostarlimab)](https://sec-api.dev/pdufa/dostarlimab) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/neoplasms-head-and-neck.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Neoplasms, Head and Neck FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/neoplasms-head-and-neck

```bibtex
@misc{secapidev_indications_neoplasms_head_and_neck_20261116,
  title        = {Neoplasms, Head and Neck FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/neoplasms-head-and-neck}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_neoplasms_head_and_neck_20261116","title":"Neoplasms, Head and Neck FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/neoplasms-head-and-neck","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
